Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants
- 19 October 2023
- Vol. 41 (48) , 7116-7128
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal modelScience, 2020
- DNA vaccine protection against SARS-CoV-2 in rhesus macaquesScience, 2020
- SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparednessNature, 2020
- Prefusion RSV F Immunization Elicits Th2-Mediated Lung Pathology in Mice When Formulated With a Th2 (but Not a Th1/Th2-Balanced) Adjuvant Despite Complete Viral ProtectionFrontiers in Immunology, 2020
- Development of an inactivated vaccine candidate for SARS-CoV-2Science, 2020
- Adjuvant selection impacts the correlates of vaccine protection against Ebola infectionVaccine, 2020
- Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and AlpacasViruses, 2019
- Delta inulin-based adjuvants promote the generation of polyfunctional CD4+ T cell responses and protection against Mycobacterium tuberculosis infectionScientific Reports, 2017
- Advax™, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safetyVaccine, 2015
- Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic ImmunopathologyJournal of Virology, 2015